Title : Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.

Pub. Date : 2020 Feb

PMID : 31922424






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In November 2017, sunitinib was approved in the USA as the first adjuvant therapy for patients at high risk for recurrent RCC postnephrectomy based on results from the S-TRAC trial. Sunitinib T cell receptor alpha constant Homo sapiens